ISRG Intuitive Surgical, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ISRG Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$535.0
Analyst Target
$608.26
+13.7%
Upside
52W High
$616.0
52W Low
$425.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$191.78B
P/E
70.58
ROE
16.9%
Profit margin
28.6%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
Intuitive Surgical exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust financial performance across profitability, leverage, and operating efficiency. Despite this, the stock trades at a significant premium to both its Graham Number ($90.2) and intrinsic value estimate ($223.61), currently priced at $535.00, reflecting high growth expectations. While revenue and earnings growth remain strong—22.9% and 25.0% YoY respectively—and margins are industry-leading, elevated valuation multiples and recent insider selling raise caution. Analysts maintain a 'buy' recommendation with a target price of $608.26, suggesting further upside is priced in despite near-term technical weakness.
Key Strengths
Exceptional profitability with gross margin of 66.38%, operating margin of 30.33%, and net margin of 28.58%
Strong Piotroski F-Score of 8/9, reflecting high-quality earnings, consistent growth, and solid balance sheet trends
Robust year-over-year revenue and earnings growth at 22.9% and 25.0%, outpacing sector averages
High return metrics including ROE of 16.90% and ROA of 9.56%, signaling efficient capital use
Consistent earnings beat streak with 3 out of last 4 quarters exceeding estimates and an average surprise of 13.06%
Key Risks
Extremely high valuation with P/E of 70.58 and Forward P/E of 55.11, significantly above sector and historical norms
Current price ($535.00) trades at over 2.4x the Graham Number ($90.2) and more than double the intrinsic value estimate ($223.61), implying substantial growth already priced in
Recent insider activity is bearish, with $28.97M in net sales over the past 6 months and no insider buys
Technical trend score of 0/100 indicates strong near-term bearish momentum, with 1W and 1M returns of -8.7% and -3.9% respectively
Missing key financial data (Altman Z-Score, ROIC, debt/equity, cash/debt levels) limits full assessment of financial health and leverage risk
AI Fair Value Estimate
Based on comprehensive analysis
$245.0
-54.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
57
Moderate
32
80
85
88
0
AI Verdict
Moderately bullish on fundamentals, but constrained by valuation and technicals
Key drivers: High Piotroski F-Score and strong earnings growth, Premium valuation multiples and insider selling as headwinds, Analyst target implies 13.7% upside, supporting moderate optimism
Confidence
85%
Value
32/100
Ref P/E, PEG, Graham Number
Positives
- Intrinsic value estimate of $223.61 provides a conservative floor benchmark
Watchpoints
- Current price is 140% above Graham Number
- P/E of 70.58 and Price/Book of 11.22 are extremely high
- PEG unavailable, but implied PEG is elevated given growth rates
Future
80/100
Ref Growth rates
Positives
- Revenue growth of 22.9% and earnings growth of 25.0% YoY
- Q/Q EPS growth of 24.7% and consistent beat rate
- Analyst target price implies confidence in future execution
Watchpoints
No urgent risks highlighted.
Past
85/100
Ref Historical trends
Positives
- 24 out of 25 quarters beat or met EPS estimates
- Long-term earnings progression shows consistent upward trajectory
- 5Y total return of +106.2% outperforms sector
Watchpoints
- 1Y return of -8.4% indicates recent underperformance
Health
88/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 indicates strong financial health
- Current ratio of 4.73 and quick ratio of 3.49 signal exceptional liquidity
Watchpoints
- Altman Z-Score not available, limiting distress risk assessment
- Debt/Equity and total debt/cash figures missing
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend program; payout ratio is 0%
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$535.0
Analyst Target
$608.26
Upside/Downside
+13.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ISRG and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ISRG
Intuitive Surgical, Inc.
Primary
|
+106.2% | +104.4% | -8.4% | +3.2% | -3.9% | -8.7% |
|
ABT
Abbott Laboratories
Peer
|
+2.6% | +1.2% | -11.2% | -14.3% | -13.5% | -11.8% |
|
AMGN
Amgen Inc.
Peer
|
+81.6% | +74.5% | +20.8% | +34.4% | +0.6% | -0.9% |
|
DHR
Danaher Corporation
Peer
|
+15.2% | -1.7% | -1.8% | +24.6% | +6.2% | -1.0% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+125.7% | +62.5% | +40.1% | +17.0% | +2.9% | +3.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
70.58
Forward P/E
55.11
PEG Ratio
N/A
P/B Ratio
11.22
P/S Ratio
19.95
EV/Revenue
19.23
EV/EBITDA
54.19
Market Cap
$191.78B
Profitability
Profit margins and return metrics
Profit Margin
28.58%
Operating Margin
30.33%
Gross Margin
66.38%
ROE
16.9%
ROA
9.56%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.9%
Earnings Growth
+25.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+24.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
4.73
Strong
Quick Ratio
3.49
Excellent
Cash/Share
$13.85
Quarterly Earnings History
EPS performance vs analyst estimates
2026-01-22
$N/A
2025-10-21
$2.4
+20.7% surprise
2025-07-22
$2.19
+14.1% surprise
2025-04-22
$1.81
+4.4% surprise
Healthcare Sector Comparison
Comparing ISRG against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
70.58
This Stock
vs
164.56
Sector Avg
-57.1%
(Discount)
Return on Equity (ROE)
16.9%
This Stock
vs
-52.77%
Sector Avg
-132.0%
(Below Avg)
Profit Margin
28.58%
This Stock
vs
-20.78%
Sector Avg
-237.6%
(Weaker)
Revenue Growth
22.9%
This Stock
vs
137.39%
Sector Avg
-83.3%
(Slower)
Current Ratio
4.73
This Stock
vs
3.36
Sector Avg
+40.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $191.78B | 70.58 | 16.9% | 28.6% | $535.0 | |
|
ABT
Abbott Laboratories
|
NEUTRAL | $186.96B | 29.19 | 13.2% | 14.7% | $107.42 | |
|
AMGN
Amgen Inc.
|
NEUTRAL | $197.41B | 25.7 | 106.1% | 21.0% | $366.21 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $168.98B | 48.46 | 6.8% | 14.4% | $235.99 | |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $154.99B | 19.34 | 40.7% | 27.9% | $124.91 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | BROSIUS MARK PRESTON | Officer | Sale | 4,964 | $2,717,619 |
| 2025-12-12 | BROSIUS MARK PRESTON | Officer | Option Exercise | 4,500 | $358,370 |
| 2025-12-12 | BROSIUS MARK PRESTON | Officer | Option Exercise | 4,500 | $358,370 |
| 2025-12-12 | BROSIUS MARK PRESTON | Officer | Sale | 4,812 | $2,633,896 |
| 2025-12-10 | CURET MYRIAM J | Officer | Option Exercise | 104 | $23,857 |
| 2025-12-10 | CURET MYRIAM J | Officer | Sale | 104 | $58,230 |
| 2025-12-01 | GUTHART GARY S | Officer and Director | Option Exercise | 25,500 | $3,557,760 |
| 2025-12-01 | CURET MYRIAM J | Officer | Option Exercise | 125 | $26,112 |
| 2025-12-01 | GUTHART GARY S | Officer and Director | Sale | 22,806 | $13,019,722 |
| 2025-12-01 | CURET MYRIAM J | Officer | Sale | 125 | $71,124 |
| 2025-11-12 | LEONARD KEITH R JR | Director | Gift | 1,606 | - |
| 2025-11-12 | BARRATT CRAIG H | Director | Option Exercise | 750 | $53,492 |
| 2025-11-12 | CHARLTON HENRY L | Officer | Option Exercise | 9,000 | $2,069,552 |
| 2025-11-12 | BARRATT CRAIG H | Director | Sale | 750 | $435,000 |
| 2025-11-12 | CHARLTON HENRY L | Officer | Sale | 13,731 | $7,963,980 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
29 analysts
Bernstein
2026-01-09
Outperform
Outperform
Barclays
2026-01-07
Overweight
Overweight
BTIG
2026-01-07
Buy
Buy
Truist Securities
2025-12-18
Buy
Buy
RBC Capital
2025-12-17
Outperform
Outperform
Citigroup
2025-12-11
Buy
Neutral
UBS
2025-10-23
Neutral
Neutral
Raymond James
2025-10-22
Outperform
Outperform
Piper Sandler
2025-10-22
Overweight
Overweight
RBC Capital
2025-10-22
Outperform
Outperform
Past News Coverage
Recent headlines mentioning ISRG from our newsroom.
Newest → oldest
No matching news yet.